Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis

Aldo V. Bono, Tania Pannellini, Marcella Liberatore, Rodolfo Montironi, Sergio Cosciani Cunico, Liang Cheng, Francesco Sasso, Piero Musiani, Manuela Iezzi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice. STUDY DESIGN: Forty-four TRAMP mice were randomly divided into 2 groups of 22 and assigned to daily treatment by gavage with vehicle only or Sorafenib from the 10th to the 26th week of age. At 26 weeks of age the mice were killed, and their genitourinary apparatus was removed and examined by histology, immunohistochemistry and confocal microscopy. RESULTS: Sorafenib reduced HGPIN growth and progression to ADC and was probably also effective in PDC inhibition. The major effect of Sorafenib was on tumor angiogenesis. Interestingly a dissociation between endothelial cells and pericytes was noted in treated PDC since inhibition of pericyte recruitment was less complete than that of endothelial cells. CONCLUSION: Sorafenib's potent antiangiogenic action may be supposed to be exerted primarily by inhibiting endothelial proliferation and sprouting, whereas its inhibition of pericyte recruitment and maturation is less complete. These observations suggest that Sorafenib's effects could be improved by the joint employment of substances capable of interfering with the recruitment and organization of pericytes.

Original languageEnglish
Pages (from-to)136-145
Number of pages10
JournalAnalytical and Quantitative Cytology and Histology
Volume32
Issue number3
StatePublished - Jun 2010

Fingerprint

Pericytes
Transgenic Mice
Prostate
Prostatic Neoplasms
Adenocarcinoma
Growth
Neoplasms
Carcinoma
Endothelial Cells
Confocal Microscopy
sorafenib
Histology
Joints
Immunohistochemistry
Organizations

Keywords

  • Angiogenesis
  • Pericytes
  • Prostate cancer
  • Sorafenib
  • Transgenic adenocarcinoma mouse prostate

ASJC Scopus subject areas

  • Anatomy
  • Histology

Cite this

Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. / Bono, Aldo V.; Pannellini, Tania; Liberatore, Marcella; Montironi, Rodolfo; Cunico, Sergio Cosciani; Cheng, Liang; Sasso, Francesco; Musiani, Piero; Iezzi, Manuela.

In: Analytical and Quantitative Cytology and Histology, Vol. 32, No. 3, 06.2010, p. 136-145.

Research output: Contribution to journalArticle

Bono, Aldo V. ; Pannellini, Tania ; Liberatore, Marcella ; Montironi, Rodolfo ; Cunico, Sergio Cosciani ; Cheng, Liang ; Sasso, Francesco ; Musiani, Piero ; Iezzi, Manuela. / Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. In: Analytical and Quantitative Cytology and Histology. 2010 ; Vol. 32, No. 3. pp. 136-145.
@article{809d78f7db9e4548ba25abec7bdbcc36,
title = "Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis",
abstract = "OBJECTIVE: To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice. STUDY DESIGN: Forty-four TRAMP mice were randomly divided into 2 groups of 22 and assigned to daily treatment by gavage with vehicle only or Sorafenib from the 10th to the 26th week of age. At 26 weeks of age the mice were killed, and their genitourinary apparatus was removed and examined by histology, immunohistochemistry and confocal microscopy. RESULTS: Sorafenib reduced HGPIN growth and progression to ADC and was probably also effective in PDC inhibition. The major effect of Sorafenib was on tumor angiogenesis. Interestingly a dissociation between endothelial cells and pericytes was noted in treated PDC since inhibition of pericyte recruitment was less complete than that of endothelial cells. CONCLUSION: Sorafenib's potent antiangiogenic action may be supposed to be exerted primarily by inhibiting endothelial proliferation and sprouting, whereas its inhibition of pericyte recruitment and maturation is less complete. These observations suggest that Sorafenib's effects could be improved by the joint employment of substances capable of interfering with the recruitment and organization of pericytes.",
keywords = "Angiogenesis, Pericytes, Prostate cancer, Sorafenib, Transgenic adenocarcinoma mouse prostate",
author = "Bono, {Aldo V.} and Tania Pannellini and Marcella Liberatore and Rodolfo Montironi and Cunico, {Sergio Cosciani} and Liang Cheng and Francesco Sasso and Piero Musiani and Manuela Iezzi",
year = "2010",
month = "6",
language = "English",
volume = "32",
pages = "136--145",
journal = "Analytical and Quantitative Cytopathology and Histopathology",
issn = "0301-102X",
publisher = "John Rylands University Library",
number = "3",

}

TY - JOUR

T1 - Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis

AU - Bono, Aldo V.

AU - Pannellini, Tania

AU - Liberatore, Marcella

AU - Montironi, Rodolfo

AU - Cunico, Sergio Cosciani

AU - Cheng, Liang

AU - Sasso, Francesco

AU - Musiani, Piero

AU - Iezzi, Manuela

PY - 2010/6

Y1 - 2010/6

N2 - OBJECTIVE: To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice. STUDY DESIGN: Forty-four TRAMP mice were randomly divided into 2 groups of 22 and assigned to daily treatment by gavage with vehicle only or Sorafenib from the 10th to the 26th week of age. At 26 weeks of age the mice were killed, and their genitourinary apparatus was removed and examined by histology, immunohistochemistry and confocal microscopy. RESULTS: Sorafenib reduced HGPIN growth and progression to ADC and was probably also effective in PDC inhibition. The major effect of Sorafenib was on tumor angiogenesis. Interestingly a dissociation between endothelial cells and pericytes was noted in treated PDC since inhibition of pericyte recruitment was less complete than that of endothelial cells. CONCLUSION: Sorafenib's potent antiangiogenic action may be supposed to be exerted primarily by inhibiting endothelial proliferation and sprouting, whereas its inhibition of pericyte recruitment and maturation is less complete. These observations suggest that Sorafenib's effects could be improved by the joint employment of substances capable of interfering with the recruitment and organization of pericytes.

AB - OBJECTIVE: To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice. STUDY DESIGN: Forty-four TRAMP mice were randomly divided into 2 groups of 22 and assigned to daily treatment by gavage with vehicle only or Sorafenib from the 10th to the 26th week of age. At 26 weeks of age the mice were killed, and their genitourinary apparatus was removed and examined by histology, immunohistochemistry and confocal microscopy. RESULTS: Sorafenib reduced HGPIN growth and progression to ADC and was probably also effective in PDC inhibition. The major effect of Sorafenib was on tumor angiogenesis. Interestingly a dissociation between endothelial cells and pericytes was noted in treated PDC since inhibition of pericyte recruitment was less complete than that of endothelial cells. CONCLUSION: Sorafenib's potent antiangiogenic action may be supposed to be exerted primarily by inhibiting endothelial proliferation and sprouting, whereas its inhibition of pericyte recruitment and maturation is less complete. These observations suggest that Sorafenib's effects could be improved by the joint employment of substances capable of interfering with the recruitment and organization of pericytes.

KW - Angiogenesis

KW - Pericytes

KW - Prostate cancer

KW - Sorafenib

KW - Transgenic adenocarcinoma mouse prostate

UR - http://www.scopus.com/inward/record.url?scp=77953039241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953039241&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 136

EP - 145

JO - Analytical and Quantitative Cytopathology and Histopathology

JF - Analytical and Quantitative Cytopathology and Histopathology

SN - 0301-102X

IS - 3

ER -